Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003037321 | SCV003441337 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2022-06-11 | criteria provided, single submitter | clinical testing | This sequence change disrupts the translational stop signal of the GALT mRNA. It is expected to extend the length of the GALT protein by 49 additional amino acid residues. This variant is present in population databases (rs111033824, gnomAD 0.003%). This protein extension has been observed in individual(s) with galactose-1-phosphate uridylyltransferase deficiency (PMID: 10649501, 15633893, 20213376, 34030713). This variant is also known as p.Ter380Arg, X380R. Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this protein extension affects GALT function (PMID: 15633893). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003037321 | SCV004198515 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-08-21 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV004790327 | SCV005413886 | pathogenic | not provided | 2024-02-09 | criteria provided, single submitter | clinical testing | PP4, PM2_moderate, PM3, PM4, PM5, PS4 |